Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients

Rha, Sun Young; Park, Yeonhee; Song, Seung Hwan; Lee, Chung Eun

doi:10.1007/s00520-016-3146-x

Cited by 15 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of CINV in the acute phase was lower than in the late phase, with a peak on the third day (43.5%) after chemotherapy infusion, for both emetogenic chemotherapies. A similar result was highlighted in previous studies, in which the incidence of nausea and vomiting was lower in the acute phase 9 , 13 .…”

Section: Discussionsupporting

confidence: 91%

“…The occurrence of vomiting (29.4%) in the late phase was higher than that found in a previous study (23%) 13 - 14 . When comparing the incidence of late vomiting by emetogenic chemotherapy (HEC: 38.8% and MEC: 17.1%) we also found a higher proportion than that found by other authors (19.2% for HEC and 16.1% for MEC) 12 .…”

Section: Discussioncontrasting

confidence: 74%

“…Acute nausea presented a lower incidence (31%) when compared with a recent study 13 (46%) which was composed of patients who were also undergoing both emetogenic chemotherapies (HEC and MEC). The occurrence of late nausea (54.6%) was also lower than that reported in the aforementioned study, which found an incidence of 82.7% 13 .…”

Section: Discussioncontrasting

confidence: 57%

See 2 more Smart Citations

Fatores de risco associados a náuseas e vômitos induzidos por quimioterapia antineoplásica

Simino¹,

Reis²,

Acúrcio³

et al. 2020

Rev. saúde pública

View full text Add to dashboard Cite

OBJETIVO: Estimar a incidência e avaliar os fatores de risco para náuseas e vômitos induzidos por antineoplásicos com alto e moderado potencial emético em pacientes adultos, no primeiro ciclo de tratamento. MÉTODOS: Estudo de coorte prospectiva, com 269 adultos acompanhados durante o primeiro ciclo de quimioterapia antineoplásica. A incidência de náuseas e vômitos foi avaliada na fase aguda (0–24 horas), na fase tardia (24 horas–5º dia) e na fase total (0–5º dia). RESULTADOS: 152 pacientes foram submetidos a quimioterápico com alto potencial emético e 117 a moderado potencial emético. A frequência relativa de náuseas foi maior quando comparada à de vômitos na fase aguda (p < 0,001) e na fase tardia (p < 0,001). Os fatores de risco identificados foram: faixa etária ≤ 49 anos (odds ratio = 0,47; IC95% 0,23–0,95) e 50–64 anos (odds ratio = 0,45; IC95% 0,23–0,87), uso de tabaco (odds ratio = 0,35; IC95% 0,14–0,88) e alto potencial emético dos quimioterápicos (odds ratio 0,55; IC95% 0,31–0,95). CONCLUSÃO: A incidência de náuseas foi maior do que a de vômitos, e na fase tardia os efeitos adversos foram mais frequentes. Os resultados sugerem que os fatores de risco para náuseas e vômitos induzidos por quimioterapia são o tabaco, a idade (adultos jovens) e o alto potencial emético do quimioterápico.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussioncontrasting

confidence: 74%

See 1 more Smart Citation

Fatores de risco associados a náuseas e vômitos induzidos por quimioterapia antineoplásica

Simino¹,

Reis²,

Acúrcio³

et al. 2020

Rev. saúde pública

View full text Add to dashboard Cite

show abstract

“…We will need to assess the association between behavioral factors and intensity of CINV to address this issue further in detail. Our data, together with previous reports, 3,4,14,15,[20][21][22][23] suggest that female gender, use of NSAIDs, susceptibility to motion sickness, and anxiety owing to their chemotherapy are risk factors for CINV. Although multivariate logistic regression analysis can identify robust factors, the multivariate model failed to converge due to insufficient sample size and the potential interactions among the factors (e.g.…”

Section: Discussionsupporting

confidence: 81%

“…4,[20][21][22][23] In addition to chemotherapy, radiation therapy, 3,13) opioid therapy, 14,15) and concomitant use of NSAIDs have also been identified as factors that increase the incidence and intensity of CINV, as they are highly likely to cause gastrointestinal problems. Factors that predict nausea, vomiting, and anxiety have been reported to be risk factors for CINV as well.…”

Section: Discussionmentioning

confidence: 99%

An Analysis of Behavioral and Genetic Risk Factors for Chemotherapy-Induced Nausea and Vomiting in Japanese Subjects

Mukoyama

Yoshimi

Goto

et al. 2016

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

There are individual differences in the frequency of chemotherapy-induced nausea and vomiting (CINV) in cancer patients. We investigated the individual variability in susceptibility to CINV with focus on both behavioral factors and genetic factors in Japanese cancer patients. We performed a prospective study to investigate the association between patient attributes (backgrounds and habits as well as gene polymorphisms) and anorexia, nausea, or vomiting in 55 Japanese cancer patients undergoing chemotherapy at Nagoya University Hospital. We found that gender (female), use of non-steroidal anti-inflammatory drugs, susceptibility to motion sickness, and anxiety were associated with the frequency of CINV. Gene polymorphisms of rs1076560 (dopamine D 2 receptor gene), rs6766410 (serotonin 5-HT 3C receptor gene) and rs4680 (catechol-Omethyltransferase gene) were also associated. Our data suggest that these attributes may thus be risk factors for CINV. Our results provide novel information that can be used to predict the incidence of CINV in Japanese patients undergoing chemotherapy; this can help provide a substantial improvement in supportive care for patients with different types of cancer.Key words chemotherapy; anorexia; nausea; vomiting; gene polymorphism; risk factor Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing side effects of chemotherapy. Inadequately controlled emesis impairs functional activity and QOL for patients, increases the use of health care resources, and may occasionally compromise adherence to treatment.1,2) According to the American Society of Clinical Oncology Clinical Practice Guidelines regarding antiemetic agents in oncology, a three-drug combination of a serotonin 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonist, dexamethasone, and aprepitant is recommended before chemotherapy treatments that have high emetic risks. If this is insufficient, substituting a high-dose of intravenous metoclopramide for the serotonin 5-HT 3 receptor antagonist or adding a dopamine D 2 receptor antagonist to the regimen is considered. 3,4) In recent years, a new class of antiemetic therapies represented by neurokinin-1 (NK-1) receptor antagonists has been introduced into clinical practice. An NK-1 receptor antagonist, aprepitant, combined with dexamethasone and the serotonin 5-HT 3 receptor antagonist ondansetron, have been shown to ameliorate CINV in both high and moderate emetic risk chemotherapy patients. 4,5) In spite of antiemetic therapy being administered according to the guidelines for CINV treatment, an incidence rate of 25-38% for delayed emesis and 55-60% for delayed nausea has been observed.4) The mechanisms underlying interpatient variability in response to treatment are not clear but are believed to be due, in part, to genetic factors. To that end, some polymorphisms in the serotonin 5-HT 3 receptor genes were investigated for their relationship with CINV. [6][7][8] There is also the possibility that polymorphisms of genes that play functional molecular or phys...

show abstract

Gaps exist between patients’ experience and clinicians’ awareness of symptoms after chemotherapy: CINV and accompanying symptoms

Rha

Song

Lee

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

Gaps exist between patients' symptom experience and clinicians' symptom awareness. Clinicians overestimated the patients' CINV experience and set less stringent symptom control goals. Enhancing clinicians' understanding of patients' symptom experience and retargeting the CINV management goals are the next steps for advancing symptom management. Symptoms other than CINV require more attention to set symptom management priorities reflecting patient experience and clinical significance.

show abstract

Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients

Cited by 15 publications

References 42 publications

Fatores de risco associados a náuseas e vômitos induzidos por quimioterapia antineoplásica

Fatores de risco associados a náuseas e vômitos induzidos por quimioterapia antineoplásica

An Analysis of Behavioral and Genetic Risk Factors for Chemotherapy-Induced Nausea and Vomiting in Japanese Subjects

Gaps exist between patients’ experience and clinicians’ awareness of symptoms after chemotherapy: CINV and accompanying symptoms

Contact Info

Product

Resources

About